Aernoud Fiolet

297 Predictors of early intolerance to low-dose colchicine in patients with coronary disease Table 1: Baseline characteristics stratified by tolerance Characteristic Intolerant population Tolerant population (N=322) (N=3618) Age – yr 66.1 ± 8.9 65.1 ± 8.6 Female sex – no. (%) 76 (23.6%) 594 (16.4%) Non-caucasian race – no. (%) 10 (3.1%) 101 (2.8%) Body Mass Index – kg/m² 27.5 ± 4.1 27.9 ± 4.1 Current smoker – no. (%)† 43 (13.4%) 568 (15.7%) Hypertension – no. (%) 163 (50.6%) 1783 (49.3%) Diabetes – no. (%) 49 (15.2%) 662 (18.3%) Insulin dependent – no. (%) 10 (3.1%) 191 (5.3%) Renal function‡ Stage 1, 2 – no. (%) 286 (88.8%) 3332 (92.1%) Stage 3a – no. (%) 36 (11.2%) 286 (7.9%) Prior myocardial infarction– no. (%) 184 (57.1%) 3126 (86.4%) History of atrial fibrillation – no. (%) 43 (13.4%) 459 (12.7%) History of left ventricular ejection fraction < 50% 39 (12.1%) 365 (10.1%) Medication use Any antiplatelet agent or anticoagulant – no. (%) 320 (99.4%) 3607 (99.7%) Anticoagulant – no. (%) 45 (14.%) 518 (14.3%) Statin – no. (%) 299 (92.9%) 3350 (92.6%) Ezetimibe – no. (%) 61 (18.9%) 852 (23.5%) Renin angiotensin inhibitor – no. (%) 217 (67.4%) 2557 (70.7%) Beta-blocker – no. (%) 211 (65.5%) 2436 (67.3%) Calcium-channel blocker – no. (%) 74 (23.1%) 778 (21.5%) *Plus-minus values are means and standard deviation. †For 21 participants information on smoking was missing. ‡Stage 1 refers to an estimated glomerular filtration rate of ≥ 90 ml/min per 1.73m² (normal or high), stage 2 to 60-89 ml/min per 1.73m² (mildly decreased), and stage 3a to 45-59 ml/min per 1.73m 2 (mildly to moderately decreased). Stages are based on the Clinical Practice Guideline of Kidney Disease: Improving Global Outcomes (KDIGO) (Kellum, J.A., et al, Kidney International Supplements, 2(1), 1-138)